dndn - prr ( at least... a 34 bagger )

More good news stories / articles on the Dendreon (DNDN) in the US

.. remembering that Prima Biomed (PRR) is 'hot on the heels ' of DNDN's success

.. with Prima applying the same technologies for its cVac as Dendreon's FDA , in production 'Provenge' ... it should be realised that every hurdle that DNDN encounters and how it overcomes those challenges can only make PRR's eventual commercial manufacturing methodology better.

. and as DNDN market capitalisation grows to what is touted to become soon $10 billion (ten thousand million ! ) ... so is the likely hood of Prima's potential market cap ( currently now $286 million ) to achieve the same figure ( and thats a 34 - 35 bagger in my books )

.. and before you jump on it ... don't forget that PRR is not a 'one trick pony'

.. cliches aside, we must remember that cVac is undoubtedly going to have a far wider scope than Provenge... and so will it's market.. and potentially it's market cap... and ultimately the share price for you and me

... PRR shares do indeed have the potential to be 'the golden ticket' .... just be patient.

the article dated April 19, 2011

" Dendreon's Price Run May Be in Anticipation of Stronger Earnings

... After spending a few months hovering in the low to mid $30 range, shares of Dendreon (DNDN) finally broke through the forty dollar mark again, having realized a ten dollar gain in just under a month.

No significant news was associated with the recent price rise, although developments over the past few months have Dendreon well on its way into a golden age, and might have sparked this run.

With quarterly results due out soon, and taking into consideration recent developments, DNDN could soon approach the fifty five dollar mark set as a general price target by analysts.

Dendreon posted revenue of $25 million on sales of Provenge for the fourth quarter of last year, a number that will only be considered a starting point for 2011.

Although the FDA approved 36 additional work stations at the company's New Jersey Provenge Manufacturing plant during the first quarter of 2011, it's unlikely that they were approved in time during the quarter to enable production to make a serious dent in the demand for the treatment.

Those work stations will, however, come into play during the ongoing second quarter. With the quadruple in production capability at the Jersey plant, a quarter of $100 million in revenue could be in the works for 2Q.

Another piece of good news that has contributed to the swift run in the DNDN share price came from the U.S. Center for Medicare and Medicaid Services (CMS) last month, when it was recommended that Provenge be covered in its entirety by the CMS.

Given the recent stock price run and positive news developments for Dendreon, the lofty expectations previously emphasized by the company and its investors are quickly coming to fruition. "

for those who want the link, see below

http://seekingalpha.com/article/264219-dendreon-s-price-run-may-be-in-anticipation-of-stronger-earnings

So ( as I scratch my head ) ... why would you want to sell PRR ?